Clinical trial
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
NCT00143520
Study timeline
Study start (unknown)2004-12-01Date precision: month
Registry last updated2021-05-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 2 Diabetesunresolved
Interventions
Sponsors & collaborators
Daiichi Sankyolead sponsor
Mapped research locations
HoustonTexas, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1St LouisMissouri, United States1MiamiFlorida, United States1San AntonioTexas, United States1PittsburghPennsylvania, United States1BirminghamAlabama, United States1CincinnatiOhio, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00143520 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.